Show simple item record

dc.contributor.advisorHossain, Dr M. Zulfiquer
dc.contributor.advisorKabir, Dr Eva Rahman
dc.contributor.authorAbid, Md. Shadman Ridwan
dc.date.accessioned2018-02-11T09:24:34Z
dc.date.available2018-02-11T09:24:34Z
dc.date.copyright2017
dc.date.issued2017-07
dc.identifier.otherID 13146046
dc.identifier.urihttp://hdl.handle.net/10361/9441
dc.descriptionThis project report is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2017.en_US
dc.descriptionCataloged from PDF version of project report.
dc.descriptionIncludes bibliographical references (page 61-67).
dc.description.abstractEpigenetic therapy has received much attention in the field of oncology in recent years. A growing recognition of the influence of epigenetic modifications in tumorigenesis and the clinical success of several drugs that reverse the aberrant epigenetic alterations have positioned epigenetic therapy at the forefront of anti-cancer drug development. Several epigenetic enzymes such as DNA methyltransferase, histone deacetylase, topoisomerase, and EZH2 have been successfully targeted by small molecule inhibitors. Potential epigenetic modifiers are continuously being optimized for bioavailability, half-life, metabolism, and most importantly target specificity. Discovery of new compounds has also broadened the pipeline of latest epi-drugs. Considering the prospect of success of epigenetic therapy against lethal malignancies, in this review we aspire to describe how different abnormal epigenetic patterns such as excessive DNA methylation, histone deacetylation, and defective chromatin remodeling contribute to cancer and present an overview of the current implementation of epi-drugs along with combined therapy in cancer treatment.en_US
dc.description.statementofresponsibilityMd. Shadman Ridwan Abid
dc.format.extent67 pages.
dc.language.isoenen_US
dc.publisherBRAC Universityen_US
dc.rightsBRAC University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectEpigenetic therapyen_US
dc.subjectCanceren_US
dc.subjectDNA methylationen_US
dc.titleEpigenetic therapy in canceren_US
dc.typeProject reporten_US
dc.contributor.departmentDepartment of Pharmacy, BRAC University
dc.description.degreeB. Pharmacy.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record